Research Reports | Market Assessment
September 2016

Migraine-Acute Treatments | Current Treatment | US | 2016

The acute migraine market is dominated by the oral triptans, although genericization of these agents as well as approvals in recent years of multiple non-oral triptans and non-triptans have begun to shift market dynamics. Triptans with unique modes of administration (e.g., injectable or patch formulations) provide options for migraineurs wishing to avoid GI effects and/or who may require a faster onset of therapeutic action; ergotamine derivatives, NSAIDs, opioid analgesics, and other non-opioid analgesics offer alternative mechanisms of action to triptans. The Migraine | Current Treatment overview provides a synopsis of current treatment goals, key therapies (including acute and prophylactic agents), and medical practice in the United States and EU5 markets for migraine. The Acute Migraine | Current Treatment | US detailed, expanded analysis explores how U.S. neurologists and general practitioners/primary care physicians are currently treating their migraine patients, with a particular focus on use of acute therapies, as well as insight into the factors driving such prescribing habits.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports